FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

On the other hand, Novo Nordisk's new obesity treatment, amycretin, showed significant weight loss in trial participants, potentially challenging Eli Lilly's Zepbound. BofA Securities kept their Buy ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

In the largest study of its kind, scientists have mapped out the ample health benefits of drugs like Ozempic and Wegovy, many of which extend far beyond losing weight. Published in the journal Nature ...